{
    "clinical_study": {
        "@rank": "142779", 
        "acronym": "BUCiL", 
        "arm_group": {
            "arm_group_label": "BUCiL", 
            "arm_group_type": "Experimental", 
            "description": "Sequence 1 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab if disease control. If progression --> Sequence 2\nSequence 2 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab-pemetrexed if disease control"
        }, 
        "brief_summary": {
            "textblock": "At present, the treatment of non-squamous cell lung cancer is based on chemotherapy with\n      platinum eventually associated with bevacizumab. A new treatment begins at progression.\n\n      In colo-rectal metastatic cancer, it was demonstrated that the first-line of treatment could\n      be administered according to a stop and go strategy respecting therapeutic breaks between\n      sequences of identical treatment. During these therapeutic breaks, a treatment of\n      maintenance is possibly better than an absence of treatment. These plans benefit to the\n      patients in terms of efficiency but also in terms of toxicity, in particular neurological.\n\n      The question is to know if this strategy is feasible in lung cancer."
        }, 
        "brief_title": "Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-small Cell Lung Cancer Metastatic", 
            "Nonsquamous Nonsmall Cell Neoplasm of Lung"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non squamous non small cell lung cancer histologically or cytologically confirmed\n             with no EGFR mutation.\n\n          -  Stage IV NSCLC. Patient with cerebral metastasis are eligible if the metastasis is\n             asymptomatic.\n\n          -  Measurable disease (recist criteria)\n\n          -  Age \u226518 years\n\n          -  PS0 or 1\n\n        Exclusion Criteria:\n\n          -  Mixed cancer small cells and non small cells or squamous lung cancer . EGFR mutated\n             cancer\n\n          -  History of malignant tumour excepted cervical and basocellular cancer and cancer\n             cured for at least 5 years.\n\n          -  Tumor invaded the big vessels or the proximal visible in TDM.\n\n          -  History of adjuvant or neoadjuvant chemotherapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01705184", 
            "org_study_id": "IFCT-1102", 
            "secondary_id": "2012-002647-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "BUCiL", 
                "description": "75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BUCiL", 
                "description": "7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BUCiL", 
                "description": "500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Bevacizumab", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Stop and go", 
            "Non-small cell lung cancer", 
            "Non-squamous", 
            "Bevacizumab"
        ], 
        "lastchanged_date": "July 18, 2013", 
        "link": {
            "description": "IFCT website", 
            "url": "http://www.ifct.fr"
        }, 
        "location": [
            {
                "contact": {
                    "email": "contact@ifct.fr", 
                    "last_name": "Werner HILGERS, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Avignon", 
                        "country": "France", 
                        "zip": "84918"
                    }, 
                    "name": "Avignon - Institut Sainte-Catherine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "contact@ifct.fr", 
                    "last_name": "Radj GERVAIS, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14000"
                    }, 
                    "name": "Caen - Centre Fran\u00e7ois Baclesse"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "contact@ifct.fr", 
                    "last_name": "Gerard ZALCMAN, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14000"
                    }, 
                    "name": "Caen - CHU C\u00f4te de Nacre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "contact@ifct.fr", 
                    "last_name": "Patrick DUMONT, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Chauny", 
                        "country": "France"
                    }, 
                    "name": "Centre Hospitalier"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "contact@ifct.fr", 
                    "last_name": "Olivier MOLINIER"
                }, 
                "facility": {
                    "address": {
                        "city": "Le Mans", 
                        "country": "France"
                    }, 
                    "name": "CH du Mans"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "contact@ifct.fr", 
                    "last_name": "Fabrice BARLESI"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Nord - Oncologie Multidisciplinaire & Innovations Th\u00e9rapeutiques"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "contact@ifct.fr", 
                    "last_name": "Didier DEBIEUVRE, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Mulhouse", 
                        "country": "France", 
                        "zip": "68000"
                    }, 
                    "name": "Mulhouse - CH"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "contact@ifct.fr", 
                    "last_name": "Jaafar BENNOUNA, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Nantes - Centre Ren\u00e9 Gauducheau"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jacques.cadranel@tnn.ap-hop-paris.fr", 
                    "last_name": "Jacques Cadranel, Pr", 
                    "phone": "+33.1.56.01.65.31"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75020"
                    }, 
                    "name": "Hopital Tenon - Pneumologie"
                }, 
                "investigator": {
                    "last_name": "Jacques Cadranel, pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "contact@ifct.fr", 
                    "last_name": "Pierre-Jean Souquet, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Pierre B\u00e9nite", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "HCL - Lyon Sud (Pneumologie)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "contact@ifct.fr", 
                    "last_name": "Herv\u00e9 LENA, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "Rennes - CHU"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Elisabeth QUOIX, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "63000"
                    }, 
                    "name": "Strasbourg - NHC"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.", 
        "overall_official": {
            "affiliation": "Centre Ren\u00e9 Gauducheau - Nantes", 
            "last_name": "Jaafar BENNOUNA, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients receiving 3 cycles of chemotherapy with full-dose platinum in the 2nd sequence", 
            "measure": "Feasibility", 
            "safety_issue": "Yes", 
            "time_frame": "After 3 cycles"
        }, 
        "reference": [
            {
                "PMID": "16421419", 
                "citation": "Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andr\u00e9 T, Tabah-Fisch I, de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006 Jan 20;24(3):394-400."
            }, 
            {
                "PMID": "22341744", 
                "citation": "Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01705184"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Control rate after the 2nd sequence", 
                "safety_issue": "No", 
                "time_frame": "After 3 cycles"
            }, 
            {
                "measure": "Response rate after the 1st sequence", 
                "safety_issue": "No", 
                "time_frame": "After 3 cycles"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "During Sequence 2 : at the beginning and after 3 cycles"
            }
        ], 
        "source": "Intergroupe Francophone de Cancerologie Thoracique", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Intergroupe Francophone de Cancerologie Thoracique", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}